Enanta Pharmaceuticals elects Yujiro S. Hata to board of directors

ENANTA PHARMACEUTICALS INC

Yujiro S. Hata elected as independent director, effective August 19, 2021.
Board expanded to seven members; Hata appointed to Compensation and Nominating & Corporate Governance committees.
Received non-statutory stock option for 13,144 shares vesting over 36 months.
Will receive standard non-employee director cash compensation and indemnification agreement.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Yujiro S. Hata

Director

ENTA · ENANTA PHARMACEUTICALS INC

Effective: 2021-08-19
Filed: August 23, 2021, 7:59 PM ET

The Board of Directors of Enanta Pharmaceuticals, Inc. has elected Yujiro S. Hata to serve as an independent director of the company in the class of directors whose term expires at Enanta’s 2024 annual meeting of stockholders.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Yujiro S. Hata was elected as Director at ENANTA PHARMACEUTICALS INC.

Action: elected
Role: Director

Exact text from the filing

The Board of Directors of Enanta Pharmaceuticals, Inc. has elected Yujiro S. Hata to serve as an independent director of the company in the class of directors whose term expires at Enanta’s 2024 annual meeting of stockholders.

View on SEC.gov

ENANTA PHARMACEUTICALS INC filing history →

Source: SEC EDGAR

accession 0001564590-21-045408

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.